Valproic acid as a monotherapy in methyl-CpG-binding protein 2 gene (MECP2) duplication-related epilepsy

We present the case of an eleven-year old male with MECP2 duplication. The patient presented with developmental delay and polymorphic seizure activity. The patient responded well to valproic acid (VPA) initially and upon re-challenge. This case report provides evidence for the use of VPA as an initial monotherapy for treatment of MECP2 duplication-related epilepsy.

Source: Epilepsy and Behavior Case Reports - October 9, 2018 Category: Neurology Source Type: research